News

The results, related to a secondary endpoint from the 250-patient trial, showed that 45% of patients treated with dabrafenib were still alive at two years compared to 32%

The early findings presented showed a confirmed overall response rate of 24 percent with KEYTRUDA as monotherapy, as measured by RECIST v1.1, central review (n= 7/29: 95% CI,

The phase 3 clinical trial, known as AETHERA, compared the use of single agent ADCETRIS to placebo in 329 patients with HL who were at risk of relapse.

The Janssen Research & Development, LLC ("Janssen")-sponsored registration study demonstrated a 19 percent reduction in risk of death in this study population (median OS, 34.7 vs 30.3 months,

In the U.S., the Food and Drug Administration (FDA) has accepted for priority review the Biologics License Application (BLA) for previously treated advanced melanoma and the Prescription Drug

Earlier, Merrimack entered into an exclusive license and collaboration agreement with Baxter International for MM-398 outside of the US and Taiwan. In May 2011, PharmaEngine licensed the development,

SB623 is an allogeneic cell product derived from bone marrow stromal cells isolated from healthy donors, and is currently being developed by SanBio. Compared to autologous cell therapy,

ILUVIEN 0.19mg is a sustained release intravitreal implant approved in the US for the treatment of DME in patients who have been previously treated with a course of

Fomepizole is marketed and distributed by Paladin Labs (Paladin) in Canada and is the standard treatment for ethylene glycol and methanol poisonings. In 2011, Paladin and Takeda entered